Inolabus - Company finances
|
EUR
|
2018
From: 2018-03-14
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 237,155 | 1,133,207 | 913,721 | 641,938 | 323,728 | 340,436 | 303,023 | 13,267 |
| Profit before tax | 62,802 | 434,495 | 295,250 | 136,944 | 45,639 | 61,537 | 83,768 | -3,074 |
| Net profit | 53,382 | 369,321 | 250,962 | 116,374 | 38,793 | 52,306 | 68,953 | -3,074 |
| Equity | 55,882 | 425,203 | 676,166 | 392,540 | 281,333 | 233,639 | 200,592 | 117,518 |
| Liabilities | 249,622 | 68,777 | 41,610 | 17,214 | 23,870 | 12,035 | 10,749 | 48 |
| Non-current assets | 35,393 | 28,464 | 7,133 | 3,064 | 3 | 3 | 3 | 3 |
| Current assets | 270,111 | 465,516 | 710,643 | 406,690 | 305,200 | 245,671 | 226,338 | 117,563 |
| Total assets | 305,504 | 493,980 | 717,776 | 409,754 | 305,203 | 245,674 | 226,341 | 117,566 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 13,347 | 24,369 | 18,478 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | +377.8% | -19.4% | -29.7% | -49.6% | +5.2% | -11.0% | -95.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 17.5% | 74.8% | 35.0% | 28.4% | 12.7% | 21.3% | 30.5% | -2.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 95.5% | 86.9% | 37.1% | 29.6% | 13.8% | 22.4% | 34.4% | -2.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 22.5% | 32.6% | 27.5% | 18.1% | 12.0% | 15.4% | 22.8% | -23.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 26.5% | 38.3% | 32.3% | 21.3% | 14.1% | 18.1% | 27.6% | -23.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 4.5 | 0.2 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 107,798 | 468,907 | 456,861 | 320,969 | 161,864 | 170,218 | 151,512 | 6,634 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Inolabus - Social security debts
The company had no debts to Sodra
Inolabus - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-07-12 | 2025-07-20 | 11999.97 |
| 2024-12-19 | 2024-12-23 | 0.06 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Inolabus, UAB (code 304786685) is a Private Limited Liability Company operating in wholesale of pharmaceutical and medical goods. In 2025, the latest financial year, revenue fell sharply to €13.3K from €303.0K in 2024 and €340.4K in 2023, while the company posted a net loss of €3.1K after profits of €69.0K and €52.3K in the previous two years. The 2025 profit margin was -23.2%, reflecting the weaker trading position. Over the same period, equity declined from €233.6K in 2023 to €200.6K in 2024 and €117.5K in 2025. Total assets were €117.6K in 2025, with liabilities of €48, leaving a very small debt load. The latest ratios show ROE and ROA at -2.6% and asset turnover at 0.11x, indicating limited use of the asset base to generate sales. Revenue per employee was €6.6K and profit per employee was -€1.5K, suggesting low productivity in the latest year.